easypod®, a first-of-its-kind device for the administration of growth hormone therapy, recently received two national honors from IDG’s Computerworld Honors Program and the 2008 American Business Awards® (ABA), at gala events in Washington DC and New York, respectively. easypod® was recognized as a Gold Medal Laureate by the Computerworld Honors Program and EMD Serono was named a Finalist for the “Most Innovative Company” by the ABA, also known as the Stevie® Awards, for easypod®. easypod® was nominated for its innovative technology that answered the need for a device that provided simple everyday use while monitoring patient adherence.
One of the key features offered by easypod® is preset dosing, which means patients no longer have to set their dose each day. Another unique feature is the dose confirmation screen that notifies patients when they have properly administered their treatment. easypod® also logs the date and dose of each injection, allowing healthcare professionals to monitor patient adherence.
REMARKS:
David Stern, Executive Vice President of Endocrinology, EMD Serono, Inc. stated: “EMD Serono is proud to be recognized for the breakthrough technology that can provide patients with an effective and efficient device to administer their therapy. easypod® is an example of our commitment to bringing innovation to patients in the Growth Hormone Deficiency Market and to meet unmet patient needs.”
Michael Gallagher, Founder and President, The Stevie Awards said: “ABA entries grew more than 30% this year, so being named a Finalist is more of an accomplishment than ever before. It means that independent business executives have agreed that the nominee is worthy of national recognition. We congratulate all of the Finalists on their achievement and wish them well in the competition.”
SPECIFICS:
easypod® is an award-winning delivery system marketed in the US by EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, for the administration of Saizen® [somatropin (rDNA origin) for injection], EMD Serono’s treatment for growth hormone deficiency.
easypod® was designed as part of a global collaboration and is currently available in 31 countries and received US FDA approval on October 31, 2007. easypod® received an iF product design award (International Forum Design) in November 2007; “Diario Médico” awarded easypod® as the “Best Idea” in the section of Research and Pharmacology; the Medical Design Excellence Awards® recognized easypod® as a 2007 Gold Medal recipient.
FOR MORE INFORMATION:
To learn more about easypod®, please visit www.easypodus.com
or contact:
-----Michele Baer, 973-233-0044, or via email at michele@baerconsulting.com
-----Colleen Minden, Director of Communications, Endocrinology, EMD Serono, Inc., 781-681-2192 or via email at colleen.minden@emdserono.com
Important Safety Information
easypod® is intended for use with Saizen® click.easy cartridges after training from a healthcare provider. Refer to instructions for use on www.easypodus.com for more information. Infrequent injection site reactions can occur. easypod® and Saizen® click.easy are available by prescription only. Refer to www.saizenus.com for full prescribing information. Saizen® [somatropin (rDNA origin) for injection] is indicated for the treatment of children and adults with growth hormone deficiency. Saizen® should not be used in patients with active malignancy, diabetic retinopathy, or in Prader-Willi syndrome patients with severe obesity or respiratory impairment.
